Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers

M. Lounis, MA. Rais, D. Bencherit, HA. Aouissi, A. Oudjedi, J. Klugarová, A. Pokorná, M. Klugar, A. Riad

. 2022 ; 10 (-) : 896343. [pub] 20220516

Language English Country Switzerland

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc22018397

Healthcare workers were prioritized in vaccination campaigns globally because they are exposed to the highest risk of contamination by SARS-CoV-2. This study evaluated the self-reported post-vaccination side effects of inactivated (BBIBP-CorV and CoronaVac) and adenoviral vector-based (AZD1222, Gam-COVID-Vac and Ad26.COV2.S) vaccines among Algerian healthcare workers using a validated questionnaire. The final analysis included 721 healthcare workers, with a predominance of females (59.1%) and younger individuals 20-30 years old (39.4%). Less than half (49.1%) of the respondents reported at least one local side effect, while 53.8% reported at least one systemic side effect. These side effects were more prevalent among viral vector vaccinees than inactivated virus vaccinees. The most common local side effects were injection site pain (39%) and arm pain (25.4%), while fatigue (34.4%), fever (28.4%), headache (24.8%) and myalgia (22.7%) were the most prevalent systemic side effects. The side effects appeared earlier among inactivated virus vaccines recipients and generally lasted for 2 to 3 days for the two vaccinated groups. The risk factors associated with a higher prevalence of side effects included female gender, allergic individuals, individuals with regular medication, those who contracted the COVID-19 disease and those who received two doses for both inactivated and viral-based vaccines groups. Despite the higher prevalence of post-vaccination side effects among adenoviral vector vaccines recipients, both vaccines groups were equally effective in preventing symptomatic infections, and no life-threatening side effects were reported in either vaccine group.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22018397
003      
CZ-PrNML
005      
20220804134740.0
007      
ta
008      
220720s2022 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fpubh.2022.896343 $2 doi
035    __
$a (PubMed)35651866
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Lounis, Mohamed $u Department of Agro-Veterinary Science, Faculty of Natural and Life Sciences, University of Ziane Achour, Djelfa, Algeria
245    10
$a Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers / $c M. Lounis, MA. Rais, D. Bencherit, HA. Aouissi, A. Oudjedi, J. Klugarová, A. Pokorná, M. Klugar, A. Riad
520    9_
$a Healthcare workers were prioritized in vaccination campaigns globally because they are exposed to the highest risk of contamination by SARS-CoV-2. This study evaluated the self-reported post-vaccination side effects of inactivated (BBIBP-CorV and CoronaVac) and adenoviral vector-based (AZD1222, Gam-COVID-Vac and Ad26.COV2.S) vaccines among Algerian healthcare workers using a validated questionnaire. The final analysis included 721 healthcare workers, with a predominance of females (59.1%) and younger individuals 20-30 years old (39.4%). Less than half (49.1%) of the respondents reported at least one local side effect, while 53.8% reported at least one systemic side effect. These side effects were more prevalent among viral vector vaccinees than inactivated virus vaccinees. The most common local side effects were injection site pain (39%) and arm pain (25.4%), while fatigue (34.4%), fever (28.4%), headache (24.8%) and myalgia (22.7%) were the most prevalent systemic side effects. The side effects appeared earlier among inactivated virus vaccines recipients and generally lasted for 2 to 3 days for the two vaccinated groups. The risk factors associated with a higher prevalence of side effects included female gender, allergic individuals, individuals with regular medication, those who contracted the COVID-19 disease and those who received two doses for both inactivated and viral-based vaccines groups. Despite the higher prevalence of post-vaccination side effects among adenoviral vector vaccines recipients, both vaccines groups were equally effective in preventing symptomatic infections, and no life-threatening side effects were reported in either vaccine group.
650    _2
$a vakcína Janssen proti COVID-19 $7 D000090984
650    _2
$a dospělí $7 D000328
650    12
$a COVID-19 $x epidemiologie $x prevence a kontrola $7 D000086382
650    _2
$a ChAdOx1 nCoV-19 $7 D000090985
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a zdravotnický personál $7 D006282
650    _2
$a lidé $7 D006801
650    12
$a vakcíny proti chřipce $7 D007252
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a bolest $7 D010146
650    _2
$a SARS-CoV-2 $7 D000086402
650    _2
$a mladý dospělý $7 D055815
651    _2
$a Alžírsko $x epidemiologie $7 D000462
655    _2
$a časopisecké články $7 D016428
700    1_
$a Rais, Mohammed Amir $u Department of Dentistry, Faculty of Medicine, University of Algiers Benyoucef Benkhedda, Algiers, Algeria
700    1_
$a Bencherit, Djihad $u Department of Biology, Faculty of Natural and Life Sciences, University of Ziane Achour, Djelfa, Algeria
700    1_
$a Aouissi, Hani Amir $u Scientific and Technical Research Center on Arid Regions (CRSTRA), Biskra, Algeria
700    1_
$a Oudjedi, Adda $u Institute of Science and Techniques of Physical and Sport Activities, Larbi Ben M'hidi University, Oum El Bouaghi, Algeria
700    1_
$a Klugarová, Jitka $u Czech National Center for Evidence-Based Healthcare and Knowledge Translation (Cochrane Czech Republic, Czech EBHC: JBI Center of Excellence, Masaryk University GRADE Center), Faculty of Medicine, Institute of Biostatistics and Analyses, Masaryk University, Brno, Czechia $u Department of Health Sciences, Faculty of Medicine, Masaryk University, Brno, Czechia
700    1_
$a Pokorná, Andrea $u Czech National Center for Evidence-Based Healthcare and Knowledge Translation (Cochrane Czech Republic, Czech EBHC: JBI Center of Excellence, Masaryk University GRADE Center), Faculty of Medicine, Institute of Biostatistics and Analyses, Masaryk University, Brno, Czechia $u Department of Health Sciences, Faculty of Medicine, Masaryk University, Brno, Czechia
700    1_
$a Klugar, Miloslav $u Czech National Center for Evidence-Based Healthcare and Knowledge Translation (Cochrane Czech Republic, Czech EBHC: JBI Center of Excellence, Masaryk University GRADE Center), Faculty of Medicine, Institute of Biostatistics and Analyses, Masaryk University, Brno, Czechia $u Department of Health Sciences, Faculty of Medicine, Masaryk University, Brno, Czechia
700    1_
$a Riad, Abanoub $u Czech National Center for Evidence-Based Healthcare and Knowledge Translation (Cochrane Czech Republic, Czech EBHC: JBI Center of Excellence, Masaryk University GRADE Center), Faculty of Medicine, Institute of Biostatistics and Analyses, Masaryk University, Brno, Czechia $u Department of Public Health, Faculty of Medicine, Masaryk University, Brno, Czechia
773    0_
$w MED00186211 $t Frontiers in public health $x 2296-2565 $g Roč. 10, č. - (2022), s. 896343
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35651866 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804134733 $b ABA008
999    __
$a ok $b bmc $g 1822136 $s 1169640
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 10 $c - $d 896343 $e 20220516 $i 2296-2565 $m Frontiers in public health $n Front Public Health $x MED00186211
LZP    __
$a Pubmed-20220720

Find record

Citation metrics

Archiving options